Antacids Market Revenue 2024 to 2034

Antacids Market Revenue 2024 to 2034

The global antacids market size is calculated at USD 7.47 billion in 2024 and is expected to be worth USD 10.33 billion by 2034, expanding at a CAGR of 3.30% from 2024 to 2034, as a result of the rising prevalence of GERD and ease of access and improved availability of OTC medicines.

Report ID: 10086 | Format: Databook | Published: August 2025 | Delivery: Immediate
Download Sample     Customisation Request  

Revenue,

USD USD 7.47 Bn

Forecast Year,

USD USD 10.33 Bn

CAGR, 2025 -

3.30%

Report Coverage

Worldwide

Reviewed By

Aditi Shivarkar

Reviewed By

Aman Singh

Antacids Market Size Analysis

Antacids Market Size By Formulation Type 2024 to 2034 (USD )

Formulation Type 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034
Tablet3735.003869.804009.354153.824303.404458.244618.544784.484956.265134.095318.17
Liquid2988.003054.293121.903190.863261.173332.863405.953480.463556.403633.813712.69
Other747.00792.42839.90889.52941.37995.531052.101111.181172.861237.251304.46

Antacids Market Size By Distribution Channel 2024 to 2034 (USD )

Distribution Channel 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034
Hospital Pharmacy1867.501946.442028.442113.642202.132294.052389.512488.662591.632698.562809.60
Drug Store and Retail Pharmacy4482.004592.984706.634823.014942.185064.215189.175317.115448.115582.235719.54
Online Provider1120.501177.091236.081297.561361.621428.371497.901570.341645.781724.351806.17

Antacids Market Size By Region 2024 to 2034 (USD )

Region 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034
North America2614.502715.782820.812929.713042.643159.723281.123406.993537.493672.783813.03
Europe1867.501900.281933.361966.742000.412034.342068.532102.972137.632172.492207.54
Asia-Pacific1867.501946.442028.442113.642202.132294.052389.512488.662591.632698.562809.60
Latin America597.60592.39586.35579.41571.54562.69552.80541.81529.68516.33501.71
Middle East & Africa522.90561.62602.19644.70689.22735.83784.62835.68889.10944.981003.43

Antacids Market

Our Client